文献速递儿童神经与发育行为儿童血液肿瘤与免疫

儿童和青少年医用大麻素治疗的系统综述

Medical Cannabinoids in Children and Adolescents: A Systematic Review.
PubMed 文献 · Pediatrics · 2017-01-01

该系统综述检索了截至2017年5月的文献,纳入22项研究共795名儿童和青少年参与者,评估医用大麻素在儿童和青少年中的治疗证据。结果显示,大麻素对化疗引起的恶心呕吐获益证据最强,对癫痫的获益证据逐渐增多;对痉挛状态、神经病理性疼痛、创伤后应激障碍和抽动秽语综合征的证据不足。需要更多研究评估其潜在作用及精神与神经认知不良反应。

要点

  • 化疗所致恶心呕吐是大麻素获益证据最强的适应症。
  • 癫痫的获益证据正在增加,但尚不充分。
  • 痉挛状态、神经病理性疼痛、创伤后应激障碍和抽动秽语综合征证据不足。

核心结论

  • 需要更多研究评估医用大麻素在儿童和青少年中的潜在作用,尤其鉴于州级合法化带来的可及性增加以及娱乐性大麻使用研究中发现的精神和神经认知不良反应。

研究设计与样本

  • 根据PRISMA指南,于2017年5月检索PubMed、Medline和CINAHL数据库,检索到2743条引文,审阅103篇全文,最终纳入21篇文章共22项研究,总样本795名参与者。
  • 纳入研究包括5项随机对照试验、5项回顾性病历审查、5项病例报告、4项开放标签试验、2项家长调查和1项病例系列。

主要发现

  • 大麻素对化疗引起的恶心呕吐获益证据最强。
  • 大麻素对癫痫的获益证据逐渐增多。
  • 目前证据不足以支持大麻素用于痉挛状态、神经病理性疼痛、创伤后应激障碍和抽动秽语综合征。

临床怎么用

  • 对于化疗引起的恶心呕吐,可考虑大麻素作为治疗选择,但需权衡潜在不良反应。
  • 对于癫痫,大麻素的使用应基于逐渐增多的证据谨慎评估。
  • 不推荐将大麻素用于痉挛状态、神经病理性疼痛、创伤后应激障碍或抽动秽语综合征,因证据不足。

局限性

  • 研究的方法学质量参差不齐,大多数研究缺乏对照组、样本量小且未设计用于检验结局指标的统计学显著性。
  • 研究在大麻素组成和剂量方面存在异质性,且缺乏长期随访以识别潜在不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Legalization of medical marijuana in many states has led to a widening gap between the accessibility and the evidence for cannabinoids as a medical treatment. OBJECTIVE: To systematically review published reports to identify the evidence base of cannabinoids as a medical treatment in children and adolescents. DATA SOURCES: Based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a search of PubMed, Medline, and the Cumulative Index to Nursing and Allied Health Literature databases was conducted in May 2017. STUDY SELECTION: Searching identified 2743 citations, and 103 full texts were reviewed. DATA EXTRACTION: Searching identified 21 articles that met inclusion criteria, including 22 studies with a total sample of 795 participants. Five randomized controlled trials, 5 retrospective chart reviews, 5 case reports, 4 open-label trials, 2 parent surveys, and 1 case series were identified. RESULTS: Evidence for benefit was strongest for chemotherapy-induced nausea and vomiting, with increasing evidence of benefit for epilepsy. At this time, there is insufficient evidence to support use for spasticity, neuropathic pain, posttraumatic stress disorder, and Tourette syndrome. LIMITATIONS: The methodological quality of studies varied, with the majority of studies lacking control groups, limited by small sample size, and not designed to test for the statistical significance of outcome measures. Studies were heterogeneous in the cannabinoid composition and dosage and lacked long-term follow-up to identify potential adverse effects. CONCLUSIONS: Additional research is needed to evaluate the potential role of medical cannabinoids in children and adolescents, especially given increasing accessibility from state legalization and potential psychiatric and neurocognitive adverse effects identified from studies of recreational cannabis use.

来源:Pediatrics,查看原文。版权归原作者所有。

引用

  1. Wong SS, Wilens TE. Medical Cannabinoids in Children and Adolescents: A Systematic Review. Pediatrics. 2017. PMID: 29061872. doi:10.1542/peds.2017-1818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。